Key result
Impella cuts short-term mortality ~43% vs. VA ECMO in cardiogenic shock.
Why the study?
No randomized controlled trials directly compare Impella versus VA ECMO to inform their relative safety and efficacy in cardiogenic shock.
Does Impella reduce short-term mortality and bleeding events compared to VA ECMO in patients with cardiogenic shock?
Meta-Analysis (n=1,971)
Yes
Does Impella reduce short-term mortality and bleeding events compared to VA ECMO in patients with cardiogenic shock?
In a meta-analysis of matched observational studies, initial support with Impella was associated with improved short-term survival and fewer bleeding complications compared to VA ECMO in cardiogenic shock, supporting its use as a preferred initial modality pending further randomized data.
Answers are grounded in this paper and cite their sources.
Impella was associated with lower short-term mortality than VA-ECMO in shock; leaves open confirmation in randomized trials.
Background: Veno-arterial extracorporeal membrane oxygenation (VA ECMO) and Impella, a transluminal microaxial ventricular assist device, are well-established in the management of cardiogenic shock. No randomized controlled trials (RCTs) directly compare Impella versus VA ECMO to inform their safety and efficacy in cardiogenic shock. Purpose: This study aims to conduct a systematic review and meta-analysis of propensity score-matched/adjusted studies to compare the clinical outcomes of Impella versus VA ECMO in cardiogenic shock patients. Methods: A systematic review was undertaken to identify comparative studies of Impella and VA ECMO in cardiogenic shock, which in the absence of RCTs, was limited to observational trials with propensity-matched or adjusted outcomes to account for important confounding factors between populations. In-hospital/30-day survival and bleeding events requiring transfusion were meta-analyzed using the random effects method. Results: Five propensity score-matched/adjusted studies comparing short-term survival following treatment with Impella versus VA ECMO were included. A statistically significant difference in in-hospital/30-day mortality was detected between patients treated with Impella (39.6%) versus VA ECMO (53.8%) (odds ratio [95% confidence interval]: 0.57 [0.44, 0.74]; P < 0.0001). Impella was associated with significantly fewer bleeding events requiring transfusion compared with VA ECMO (19.9% vs. 28.8%, respectively) (OR [95% confidence interval]: 0.61 [0.46, 0.80]; P = 0.0004). Conclusion: In the absence of RCTs, this meta-analysis of propensity matched/adjusted observational trials represents the highest level of evidence available to date. Impella was associated with improved short-term survival and decreased bleeding events compared to VA ECMO in patients with cardiogenic shock.
No takes yet. Share an insight, caveat, or question.
Stub et al. (2025) conducted a meta-analysis in Cardiogenic shock (n=1,971). Impella vs. Veno-arterial extracorporeal membrane oxygenation (VA ECMO) was evaluated on In-hospital/30-day mortality (OR 0.57, 95% CI 0.44-0.74, p=<0.0001). Impella reduced the odds of in-hospital/30-day mortality compared to VA ECMO (39.6% vs 53.8%; OR 0.57, p<0.0001) in patients with cardiogenic shock.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: